Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600062 | 0.84 | L3MBTL3 (0.44) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL599098 | 0.84 | L3MBTL3 (0.46) | HRH3L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL599177 | 0.81 | KDM4E (0.59) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL599543 | 0.79 | HRH3 (0.55) | HRH3L3MBTL3L3MBTL1KCNH2 | |
| SCHEMBL600329 | 0.79 | NPC1 (0.61) | NPC1RAB9AHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL7893397 | 0.78 | L3MBTL3 (0.55) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL2928056 | 0.78 | HRH3 (0.49) | HRH3KCNH2 | |
| SCHEMBL2928055 | 0.78 | HRH3 (0.49) | HRH3KCNH2 | |
| SCHEMBL599523 | 0.78 | ALDH1A1 (0.59) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL599473 | 0.78 | HRH3 (0.59) | HRH3L3MBTL3L3MBTL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | claimed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | claimed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | claimed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-2391617-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086403-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086403-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH3, HRH2, HRH1 | MAPK14 4569/4885NPC1 2650/4885TSHR 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.